HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.